← Back to Clinical Trials
Recruiting NCT07464093

NCT07464093 STABLE Pilates for Hypermobility

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07464093
Status Recruiting
Phase
Sponsor Brigham and Women's Hospital
Condition Ehlers-Danlos Syndrome (EDS)
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2026-07
Primary Completion 2026-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
PilatesEducation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 100 participants in total. It began in 2026-07 with a primary completion date of 2026-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study is looking at whether Pilates-based exercise can help with hypermobility-related symptoms, like pain.

Eligibility Criteria

Inclusion Criteria: * ≥ 18 years old; * Self-reported hypermobility with confirmed or suspected diagnosis of hEDS/HSD; * Self-reported persistent pain ≥ 3 months; * A minimum of 3/10 self-reported pain intensity in the past week * Able to get on and off the floor without assistance; * Able to communicate fluently in English; and * Able to provide written, informed consent Exclusion Criteria: * Regular ongoing mind-body practice (e.g. Tai chi, yoga, pilates) defined as a regular weekly practice of at least 20min/week over the past 6 months; * Recent surgery or acute bone, joint or nerve injury (\<6 months); * Have a history of a severe or progressive neurological or movement disorder; * Pregnant, planning to become pregnant during the study, or currently breast feeding; * Unable to get on and off the floor without assistance; * Unable to complete study procedures due to cognitive impairment; * Unable to provide written, informed consent; or * Currently participating in or planning to participate in another physical activity, mind-body or pain-related intervention research study in the next 4 months.

Contact & Investigator

Central Contact

Stephanie Voss, PhD

✉ svoss2@bwh.harvard.edu

📞 6177329181

Principal Investigator

Samantha Meints, PhD

PRINCIPAL INVESTIGATOR

Brigham and Women's Hospital

Frequently Asked Questions

Who can join the NCT07464093 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Ehlers-Danlos Syndrome (EDS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07464093 currently recruiting?

Yes, NCT07464093 is actively recruiting participants. Contact the research team at svoss2@bwh.harvard.edu for enrollment information.

Where is the NCT07464093 trial being conducted?

This trial is being conducted at Chestnut Hill, United States.

Who is sponsoring the NCT07464093 clinical trial?

NCT07464093 is sponsored by Brigham and Women's Hospital. The principal investigator is Samantha Meints, PhD at Brigham and Women's Hospital. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology